Epidemiological and clinical and laboratory features of COVID-19 in pediatric patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article presents up-to-date data on the main pathogenetic mechanisms and features of the new coronavirus infection caused by the SARS-CoV-2 virus. The review highlights the main epidemiological features of infection with SARS-CoV-2 in children at various age periods, features of the immune response and variants of the course of the disease with lung damage, as well as other organs and systems. The clinical and laboratory features of the course of a new coronavirus infection in children are highlighted. It was found that children are less likely to develop severe COVID-19 than adults. More than 95% of all cases of the disease range from asymptomatic course to clinical manifestations of mild and moderate severity. About 2% of children’s patients need hospitalization, including in the intensive care unit and ventilator. However, extrapulmonary manifestations are registered in children more often than in adults, especially from the gastrointestinal tract and circulatory organs. According to numerous authors, the features of the clinical and laboratory course of COVID-19 in pediatric patients are probably associated with a number of factors, among which age-related features of the immune response, the functioning of angiotensin-converting enzyme-2 (ACE-2) used by coronaviruses as a cellular receptor are indicated. Understanding the role of the child population in the dynamics of transmission of infection is important, since children significantly affect the rate of infection spread.

About the authors

Natalya A. Belykh

I.P. Pavlov Ryazan State Medical University

Author for correspondence.
Email: nbelyh68@mail.ru

MD, PhD, Dr. Sci. (Med), Professor, Head, Department of Faculty and Polyclinic Pediatrics with the Course of Pediatric of Postgraduate Education

Russian Federation, Ryazan

Olga A. Solovyova

I.P. Pavlov Ryazan State Medical University

Email: olgasolovejka@yandex.ru

Postgraduate Student, Department of Faculty and Polyclinic Pediatrics with the Course of Pediatric of Postgraduate Education

Russian Federation, Ryazan

Natalya A. Anikeeva

I.P. Pavlov Ryazan State Medical University

Email: natasha782@inbox.ru

MD, PhD, Associate Professor Department of Faculty and Polyclinic Pediatrics with the Course of Pediatric of Postgraduate Education

Russian Federation, Ryazan

References

  1. Abaturov AE, Agafonova EA, Krivusha EL, et al. Pathogenesis of COVID-19. Zdorov’e rebenka. 2020;15(2):133–144. (In Russ.). doi: 10.22141/2224-0551.15.2.2020.200598
  2. О sostoyanii sanitarno-ehpidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2020 godu: Gosudarstvennyi doklad. Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka; 2021. 256 p. (In Russ.) Available from: https://www.rospotrebnadzor.ru/documents/details.php? ELEMENT_ID=18266
  3. Rekomendatsii VOZ dlya naseleniya v svyazi c rasprostraneniem novogo koronavirusa (2019-nCoV): mify i lozhnye predstavleniya. (In Russ.) Available from: https://www.who.int/ru/emergencies/diseases/ novel-coronavirus-2019/advice-for-public/myth-busters
  4. Alloway BC, Yaeger SK, Mazzaccaro RJ, et al. Suspected case of COVID-19-associated pancreatitis in a child. Radiol Case Rep. 2020;15(8):1309–1312. doi: 10.1016/j.radcr.2020.06.009
  5. Bhumbra S, Malin S, Kirkpatrick L, et al. Clinical features of critical coronavirus disease 2019 in children. Pediatr Crit Care Med. 2020;21(10):e948–e953. doi: 10.1097/PCC.0000000000002511
  6. Bialek S, Gierke R, Hughes M, et al. Coronavirus disease 2019 in children United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422–426. doi: 10.15585/mmwr.mm6914e4
  7. Cai JH, Wang XS, Ge YL, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Zhonghua Er Ke Za Zhi. 2020;58(2):86–87. doi: 10.3760/cma.j.issn.0578-1310.2020.02.002
  8. CDC (2020) Coronavirus Disease 2019 (COVID-19). In: Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html
  9. Simões e Silva AC, Leal CR. Is SARS-CoV-2 vertically transmitted? Front Pediatr. 2020;8:276. doi: 10.3389/fped.2020.00276
  10. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223): 514–523. doi: 10.1016/S0140-6736(20)30154-9
  11. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2019;5:536–544. doi: 10.1038/s41564-020-0695-z
  12. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4(9):669–677. doi: 10.1016/S2352-4642(20)30215-72020/07/13
  13. de Bree LCJ, Koeken V, Joosten LAB, et al. Non-specific effects of vaccines: Current evidence and potential implications. Semin. Immunol. 2018;39:35–43. doi: 10.1016/j.smim.2018.06.002
  14. DeBiasi RL, Song X, Delaney M, et al. Severe Coronavirus Disease-2019 in children and young adults in the Washington, DC, Metropolitan Region. J Pediatr. 2020;223: 199–203E1. doi: 10.1016/j.jpeds.2020.05.007
  15. Desai A, Mills A, Delozier S, et al. Pediatric patients with SARS-CoV-2 infection: clinical characteristics in the US from a large Global Health Research Network. Cureus. 2020;12(9): E10413. doi: 10.7759/cureus.10413
  16. Ding Y, Yan H, Wenbin GW. Clinical characteristics of children with COVID19: a meta-analysis. Front Pediatr. 2020;8:431. doi: 10.3389/fped.2020.00431
  17. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6): e20200702. doi: 10.1542/peds.2020-0702
  18. Felsenstein S, Herbert JA, McNamara PS, et al. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448. doi: 10.1016/j.clim.2020.108448
  19. Grifoni A, Sidney J, Zhang Y, et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–680.E2. doi: 10.1016/j.chom.2020.03.002
  20. Hanff TC, Harhay MO, Brown TS, et al. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations. Clin Infect Dis. 2020;71(15):870–874. doi: 10.1093/cid/ciaa329
  21. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review. J eClin Med. 2020;100433. DOI: 10.1016/ j.eclinm.2020.100433;24:100433
  22. Kosmeri C, Koumpis E, Tsabouri S, et al. Hematological manifestations of SARS-CoV-2 in children. Pediatr Blood Cancer. 2020;67(12): e28745. doi: 10.1002/pbc.28745
  23. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879. doi: 10.1038/nm1267
  24. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19): 1801–1803. doi: 10.1093/eurheartj/ehaa235
  25. Leung WK, To K-F, Chan PKS, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4): 1011–1017. doi: 10.1016/s0016-5085(03)01215-0
  26. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432. DOI: 10.1002/ jmv.25685
  27. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–555. doi: 10.1002/jmv.25728
  28. Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179:1029–1046. doi: 10.1007/s00431-020-03684-7
  29. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. doi: 10.1001/jama.2020.4344
  30. Mantovani A, Rinaldi E, Zusi C, et al. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis: International Pediatric Research Foundation, Inc; 2020. Pediatr Res. 2021;89:733–737. doi: 10.1038/s41390-020-1015-2
  31. Mao L, Wang M, Chen S, et al. Neurologic Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China. Retrospective Case Series Study. Jama Neurology. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127
  32. Pain CE, Felsenstein S, Cleary G, et al. Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatol. 2020;2(7): E376–E379. doi: 10.1016/S2665-9913(20)30137-5
  33. Pandit K, Gupta S, Sharma AG. Clinico-pathogenesis of COVID-19 in children. Indian J Biochem Biophys. 2020;57(3):264–269.
  34. Posfay-Barbe KM, Wagner N, Gauthey M, et al. COVID-19 in children and the dynamics of infection in families. Pediatrics. 2020;146(2):e20201576. doi: 10.1542/peds.2020-1576
  35. Razavi A, Davoodi L, Shojaei L, et al. COVID-19 in children: a narrative review. Open Access Maced J Med Sci. 2020;8(T1):23–31. doi: 10.3889/oamjms.2020.4714
  36. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4):2000058. doi: 10.2807/1560-7917.ES.2020.25.4.2000058
  37. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. doi: 10.1016/S0140-6736(20)31094-1
  38. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453–454. doi: 10.1038/s41577-020-0367-52020/06/18
  39. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x
  40. Saleh NY, Aboelghar HM, Salem SS, et al. The severity and atypical presentations of COVID-19 infection in pediatrics. BMC Pediatrics. 2021;21:144. doi: 10.1186/s12887-021-02614-2
  41. Simões e Silva AC, Leal CR. Is SARS-CoV-2 vertically transmitted? Front Pediatr. 2020;8:276. doi: 10.3389/fped.2020.00276
  42. Song R, Han B, Song M, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. J Infect. 2020;81(2):E26–E30. doi: 10.1016/j.jinf.2020.04.018
  43. Stringhini S, Wisniak A, Piumatti G, et al., Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–319. doi: 10.1016/S0140-6736(20)31304-02020/06/15
  44. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847. doi: 10.1002/ajh.25829
  45. To KKW, Tsang OTY, et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical Infectious Diseases. 2020;71(15):841–843. doi: 10.1093/cid/ciaa149
  46. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol. 2012;2(3):264–275. doi: 10.1016/j.coviro.2012.04.004
  47. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–1778. doi: 10.1016/S0140-6736(20)31103-X
  48. Visveswaran GK, Morparia K, Narang S, et al. Severe acute respiratory syndrome coronavirus 2 infection and thrombosis: phlegmasiaceruleadolenspresenting with venous gangrene in a child. J Pediatr. 2020;226: 281–284. doi: 10.1016/j.jpeds.2020.07.032
  49. Wang L, Shi Y, Xiao T, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (first edition). Ann Transl Med. 2020;8(3):47. doi: 10.21037/atm.2020.02.20
  50. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 March, 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19 %2D%2D-11-march-2020
  51. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13): 1239–1242. doi: 10.1001/jama.2020.2648
  52. Wysocki J, Schulze A, Batlle D. Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules. 2019;9(12):886. doi: 10.3390/biom9120886
  53. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26: 502–505. doi: 10.1038/s41591-020-0817-4
  54. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X
  55. Zachariah Ph, Johnson CL, Halabi KC, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City. JAMA Pediatr. 2020;174(10)e202430. doi: 10.1001/jamapediatrics
  56. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1): 386–389. doi: 10.1080/22221751.2020.1729071
  57. Zhang YP. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41(2):145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003
  58. Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17: 259–260. doi: 10.1038/s41569-020-0360-5
  59. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis. Treatment and Prevention Options in Children. Pediatr Infectious Disease Journal. 2020;39(5): 355–368. doi: 10.1097/INF.0000000000002660

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Belykh N.A., Solovyova O.A., Anikeeva N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».